GLP-1 Healthcare Ripple
Courtney W. Holt@mootron
+4.7%
since Sep 30
The idea
I believe GLP-1 drugs are reshaping healthcare in ways the market hasn't fully priced, on both sides. So this basket owns the winners, like surgery providers and device makers set for higher volumes as patients become eligible for procedures once denied to them, plus dispensing, diagnostics, and monitoring names riding the metabolic health wave. It also holds dialysis and device companies that got sold off as if their patients vanish overnight, when that decline actually plays out over a decade.
What it owns
- Weight loss makes millions of patients newly eligible for knee, hip, and other elective surgeries they were previously turned away from. · StrykerIt is the largest maker of knee and hip replacements, so joint replacement volumes need to climb as more GLP-1 patients clear weight cutoffs for surgery., HCA HealthcareIt operates hospitals where elective knee and hip surgeries happen, so admission and surgical volumes are the clearest measure of whether rising procedures are real., Zimmer BiometIt earns most revenue from knee and hip implants, so it's the most direct read on whether GLP-1 weight loss turns denied patients into surgery candidates., Smith+NephewIt sells knee and hip replacements at lower prices than larger competitors, so it benefits if rising surgery volumes lift the entire orthopedics group.24%
- Every GLP-1 prescription flows through distributors, pharmacies, and telehealth prescribers, and that volume is growing for years. · McKessonIt distributes GLP-1 drugs from manufacturers to pharmacies and gets paid on volume, so its drug distribution revenue grows as prescriptions climb., CVS HealthIt dispenses GLP-1 prescriptions at scale through pharmacies and manages drug benefits, so results hold if prescription volume rises and CVS keeps its dispensing share., Hims & Hers HealthIt prescribes weight loss treatment online, a major entry point for new GLP-1 patients, so results hold if telehealth stays legitimate for these drugs and subscribers keep growing., CencoraIt is a major drug distributor collecting a fee on every GLP-1 shipment, so revenue holds as long as prescription demand keeps growing and distributors retain their cut.22%
- Sleep apnea and insulin device makers sold off on GLP-1 fear that so far outruns any real loss of patients. · ResMedIt makes sleep apnea devices that most patients still need even after weight loss, so device sales need to hold steady while market sentiment normalizes., InsuletIt makes insulin pumps, and type one diabetics require insulin regardless of weight while type two decline runs gradually, so pump adoption needs to keep growing., Inspire Medical SystemsIt makes sleep apnea implants hit harder by GLP-1 fear, so it rebounds if implant procedure volumes keep growing despite weight loss., Tandem Diabetes CareIt makes insulin pumps priced for decline, so even flat pump sales would outperform market expectations if pump demand doesn't actually erode quickly.20%
- As metabolic health becomes something people treat and track, lab testing and glucose monitoring expand well beyond diabetics. · DexComIt makes continuous glucose monitors used by people actively managing metabolic health beyond just diabetics, so the monitoring market needs to expand alongside GLP-1 use., LabcorpIt runs blood work that GLP-1 patients need before starting and while on the drugs, so testing volume grows as metabolic health becomes actively managed., Quest DiagnosticsIt is the other major lab operator capturing the same volume: more people managing metabolic health means more screening and monitoring tests.16%
- Dialysis stocks were punished as if patients vanish overnight, but kidney disease declines over decades, not quarters. · DaVitaIt provides dialysis services priced for overnight patient decline, but actual kidney disease decline runs a decade slower, so earnings hold steady while fear fades., Fresenius Medical CareIt provides dialysis globally at the same discount to sentiment as domestic operators, so earnings hold if treatment volumes stay steady while the market reprices decline.11%
- Cash7%